SCHEMBL73777

SCHEMBL73777

C[CH]OC(=O)OC1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8693054 0.86
SCHEMBL305154 0.82 EPHX1 (0.41)
SCHEMBL697832 0.82 EPHX1 (0.37)
SCHEMBL1023586 0.81 KAT2B (0.43) KAT2BBAZ2B
SCHEMBL73234 0.80 EPHX1 (0.44)
SCHEMBL1439730 0.80 EPHX1 (0.44)
Hydrochloric Acid SCHEMBL3966985 0.79 KAT2B (0.42) KAT2BBAZ2B
SCHEMBL73973 0.78 KAT2B (0.42) KAT2BBAZ2B
SCHEMBL1568468 0.76 CYP19A1 (0.44)
SCHEMBL73972 0.74 KAT2B (0.36) KAT2BBAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 EP disclosed
US-20240197679-A1 NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS Altrartis Therapeutics Inc. 2024-06-20 US disclosed
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2024-06-20 US disclosed
US-20240199543-A1 Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2024-06-20 US disclosed
US-20240158443-A1 Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds UNIV COLORADO REGENTS (US) 2024-05-16 US disclosed
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-04-09 US disclosed
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same MYDECINE INNOVATIONS GROUP INC. 2024-03-28 US disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 US disclosed
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same MYDECINE INNOVATIONS GROUP INC. (US) 2024-03-26 US disclosed
US-20240092747-A1 SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE Altrartis Therapeutics Inc. 2024-03-21 US disclosed
US-5510367-A TREATMENT OR PREVENTION OF NEUROTOXIC INJURIES SUCH AS CEREBRAL STROKE, HEMMORHAGIC STROKE, CEREBRAL ISCHEMIA, VASOSPASM, HYPOGLYCEMIA, ANAESIA, HYPOXIA, ASHYXIA, CARDIAC ARREST AND NEURODEGENERATIVE DISEASES GLAXO SPA (IT) 1996-04-23 US disclosed
WO-1995023149-A1 PHENYLALKYLAMINO DERIVATIVES OF CONDENSED CARBAPENEMES GLAXO WELLCOME S.P.A. (IT) 1995-08-31 WO disclosed
WO-1995013278-A1 UREA DERIVATIVES GLAXO WELLCOME S.P.A. (IT) 1995-05-18 WO disclosed
WO-1995010517-A1 INDOLE DERIVATIVES AS NMDA ANTAGONISTS GLAXO WELLCOME S.P.A. (IT) 1995-04-20 WO disclosed
WO-1995007887-A1 INDOLE DERIVATIVES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS GLAXO S.P.A. (IT) 1995-03-23 WO disclosed
US-5374649-A Nervous system disorders GLAXO S.P.A. (IT) 1994-12-20 US disclosed
US-5374648-A Nervous system disorders GLAXO S.P.A. (IT) 1994-12-20 US disclosed
US-5373018-A Antagonist to excitory amino acids on N-methyl aspartic acid receptor complex, theraputically effective in treatment of central nervous system disorder GLAXO S.P.A. (IT) 1994-12-13 US disclosed
EP-0568136-A1 Indole-2-carboxylic acid derivatives GLAXO S.p.A. (IT) 1993-11-03 EP disclosed
WO-1993021153-A1 INDOLE-2-CARBOXYLIC ACID DERIVATIVES GLAXO S.P.A. (IT) 1993-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101513-A1 Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 KAT2B 3270/4885BAZ2B 1605/4885
US-20240197679-A1 NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS PNMT, HTR2C, SLC18A2 KAT2B 1418/4885BAZ2B 4601/4885
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KAT2B 3091/4885BAZ2B 1105/4885
US-11952342-B2 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 KAT2B 3106/4885BAZ2B 1458/4885
US-20240158443-A1 Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds VIP, PTMS, QPCT KAT2B 4882/4885BAZ2B 3826/4885
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 KAT2B 767/4885BAZ2B 2703/4885
US-20240199543-A1 Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same TOP2A, PAICS, TOP1 KAT2B 3106/4885BAZ2B 1458/4885
US-11939292-B1 Aza-substituted psilocin analogs and methods of synthesizing the same TOP2A, PAICS, TOP1 KAT2B 3106/4885BAZ2B 1458/4885
US-20240092747-A1 SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE HTR3B, HTR3C, HTR3E KAT2B 1754/4885BAZ2B 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.